{"retracted":false,"update":{"timestamp":1480896000000,"doi":"10.3310/hta20350-c201611","type":"corrigendum"},"doi":"10.3310/hta20350","journal":"Health Technology Assessment","publisher":"National Institute for Health Research","title":"Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation"}
